替拉珠单抗：真实临床实践中的短期疗效与安全性 - Suppr

Suppr

超能文献

Tildrakizumab: short-term efficacy and safety in real clinical practice.

作者信息

Galán-Gutierrez Manuel, Rodriguez-Fernandez Freire Lourdes, Ruiz-Villaverde Ricardo

机构信息

Dermatology Unit, Hospital Universitario Reina Sofia, IMIBIC. Universidad de Córdoba, Córdoba, Spain.

Dermatology Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain.

出版信息

Int J Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840. Epub 2021 Oct 11.

DOI:10.1111/ijd.15840

PMID:34632570

Abstract

摘要

相似文献

Tildrakizumab: short-term efficacy and safety in real clinical practice.替拉珠单抗：真实临床实践中的短期疗效与安全性

Int J Dermatol. 2022 Sep;61(9):e355-e357. doi: 10.1111/ijd.15840. Epub 2021 Oct 11.

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).替西罗莫司治疗银屑病的疗效、药物存活率和安全性在合并和不合并代谢综合征的患者中相当：来自 2 项 3 期随机对照研究（reSURFACE 1 和 reSURFACE 2）的长期结果。

J Am Acad Dermatol. 2021 Feb;84(2):398-407. doi: 10.1016/j.jaad.2020.09.047. Epub 2020 Sep 19.

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.替西单抗（MK-3222），一种抗白细胞介素-23p19 单克隆抗体，在一项 IIb 期随机安慰剂对照试验中改善了银屑病。

Br J Dermatol. 2015 Oct;173(4):930-9. doi: 10.1111/bjd.13932. Epub 2015 Oct 15.

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.替拉珠单抗治疗中重度银屑病的长期疗效和安全性：两项随机III期临床试验（reSURFACE 1和reSURFACE 2）长达148周的汇总分析

Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18.

Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.老年银屑病患者的抗白细胞介素-23 治疗：真实世界中 Guselkumab、Risankizumab 和 Tildrakizumab 的应用。

Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.

Efficacy, safety and patient's satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature.替拉珠单抗治疗生殖器银屑病的疗效、安全性及患者满意度：病例系列及文献综述

J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e916-e918. doi: 10.1111/jdv.18368. Epub 2022 Jul 4.

Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.在现实生活中，无论之前是否使用过生物药物以及是否存在关节受累情况，替拉珠单抗治疗中重度银屑病均显示出良好疗效。

Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22.

Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).银屑病患者中，替拉珠单抗的疗效和安全性不受代谢综合征状态的影响：两项3期随机对照研究（reSURFACE 1和reSURFACE 2）的事后分析

J Am Acad Dermatol. 2020 Feb;82(2):519-522. doi: 10.1016/j.jaad.2019.09.042. Epub 2019 Sep 26.

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).替西罗莫司单抗治疗中度至重度斑块状银屑病日本患者的疗效和安全性：一项 64 周 3 期研究（reSURFACE 1）的结果。

J Dermatol. 2021 Jun;48(6):853-863. doi: 10.1111/1346-8138.15789. Epub 2021 Feb 25.

The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis.替拉珠单抗的潜在效用：一种用于治疗银屑病的白细胞介素-23抑制剂。

Expert Opin Investig Drugs. 2017 Feb;26(2):243-249. doi: 10.1080/13543784.2017.1274734. Epub 2017 Jan 1.

引用本文的文献

Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study.替拉珠单抗治疗掌跖受累斑块状银屑病的真实生活经验：一项意大利多中心回顾性研究

Dermatol Ther (Heidelb). 2025 Feb;15(2):323-336. doi: 10.1007/s13555-025-01339-9. Epub 2025 Jan 23.

A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice.临床实践中使用替拉珠单抗治疗斑块状银屑病患者的3年经验

Dermatol Ther (Heidelb). 2024 Sep;14(9):2645-2652. doi: 10.1007/s13555-024-01252-7. Epub 2024 Aug 27.

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023.替拉珠单抗的安全性：基于2018 - 2023年美国食品药品监督管理局不良事件报告系统（FAERS）数据库的不成比例性分析

Front Pharmacol. 2024 Jul 10;15:1420478. doi: 10.3389/fphar.2024.1420478. eCollection 2024.

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.转换为替拉珠单抗后的有效性和安全性：一项意大利多中心银屑病真实世界研究

Dermatol Pract Concept. 2023 Oct 1;13(4):e2023215. doi: 10.5826/dpc.1304a215.

Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).真实世界中替度鲁单抗治疗慢性斑块状银屑病的疗效：一项为期 52 周的多中心回顾性研究-IL PSO（意大利斑块状银屑病研究）。

J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93-103. doi: 10.1111/jdv.18594. Epub 2022 Oct 5.

Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.5年中不同体重的中度至重度银屑病患者使用替拉珠单抗的疗效：来自reSURFACE关键研究的汇总分析

Dermatol Ther (Heidelb). 2022 Oct;12(10):2325-2341. doi: 10.1007/s13555-022-00793-z. Epub 2022 Sep 13.

Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain).替拉珠单抗：西班牙安达卢西亚地区三家三级医院的中期（52周）疗效、安全性及生存率研究

J Clin Med. 2022 Aug 30;11(17):5098. doi: 10.3390/jcm11175098.

Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT.在斑块状银屑病的长期治疗中，替拉珠单抗的真实世界疗效和安全性：来自非干预性、前瞻性、多中心研究 TILOT 的结果。

J Eur Acad Dermatol Venereol. 2023 Jan;37(1):85-92. doi: 10.1111/jdv.18572. Epub 2022 Sep 23.

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.替拉珠单抗治疗难治性部位（头皮、指甲、掌跖和生殖器银屑病）的疗效

J Clin Med. 2022 May 7;11(9):2631. doi: 10.3390/jcm11092631.

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.替拉珠单抗治疗中重度斑块状银屑病：一项多中心、回顾性、真实世界研究。

Dermatol Ther. 2022 Jun;35(6):e15488. doi: 10.1111/dth.15488. Epub 2022 Apr 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验